Roche Holding AG

BIT:1ROG Stock Report

Market Cap: €320.1b

Roche Holding Valuation

Is 1ROG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 1ROG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 1ROG (€362) is trading below our estimate of future cash flow value (€670.25)

Significantly Below Future Cash Flow Value: 1ROG is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1ROG?

Key metric: As 1ROG is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1ROG. This is calculated by dividing 1ROG's market cap by their current earnings.
What is 1ROG's PE Ratio?
PE Ratio31.4x
EarningsCHF 9.43b
Market CapCHF 297.13b

Price to Earnings Ratio vs Peers

How does 1ROG's PE Ratio compare to its peers?

The above table shows the PE ratio for 1ROG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.9x
REC Recordati Industria Chimica e Farmaceutica
23.6x13.73%€9.6b
MRK Merck
14.2x5.06%US$275.8b
JNJ Johnson & Johnson
19.6x1.57%US$525.3b
AZN AstraZeneca
30.2x12.59%UK£210.3b
1ROG Roche Holding
31.4x12.84%€297.1b

Price-To-Earnings vs Peers: 1ROG is expensive based on its Price-To-Earnings Ratio (31.4x) compared to the peer average (22x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does 1ROG's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
1ROG 31.4xIndustry Avg. 25.3xNo. of Companies9PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1ROG is expensive based on its Price-To-Earnings Ratio (31.4x) compared to the European Pharmaceuticals industry average (25x).

Price to Earnings Ratio vs Fair Ratio

What is 1ROG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1ROG PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.4x
Fair PE Ratio52.7x

Price-To-Earnings vs Fair Ratio: 1ROG is good value based on its Price-To-Earnings Ratio (31.4x) compared to the estimated Fair Price-To-Earnings Ratio (52.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1ROG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€362.00
€368.58
+1.82%
13.80%€459.83€247.69n/a19
Jan ’27€350.00
€348.60
-0.40%
14.03%€449.19€247.16n/a18
Dec ’26€338.00
€329.17
-2.61%
15.12%€447.37€246.16n/a18
Nov ’26€280.00
€321.35
+14.77%
15.77%€450.24€247.74n/a18
Oct ’26€298.00
€320.59
+7.58%
17.09%€468.34€245.93n/a17
Sep ’26€278.00
€318.03
+14.40%
16.96%€466.44€244.93n/a18
Aug ’26€268.00
€323.78
+20.81%
15.93%€472.26€247.99n/a19
Jul ’26€278.00
€323.95
+16.53%
16.10%€485.99€235.50n/a20
Jun ’26€284.00
€323.99
+14.08%
16.10%€486.04€235.53n/a20
May ’26n/a
€325.72
0%
16.12%€484.71€234.88n/a20
Apr ’26n/a
€330.36
0%
14.50%€469.80€241.19n/a20
Mar ’26n/a
€330.72
0%
15.54%€478.91€245.87n/a20
Feb ’26n/a
€323.72
0%
15.74%€463.96€243.63n/a19
Jan ’26n/a
€325.72
0%
16.62%€472.43€246.95€350.0018
Dec ’25n/a
€324.33
0%
16.89%€472.15€236.07€338.0018
Nov ’25n/a
€324.77
0%
17.04%€468.29€235.22€280.0017
Oct ’25n/a
€322.41
0%
17.32%€469.73€234.87€298.0018
Sep ’25n/a
€315.14
0%
17.07%€469.03€234.52€278.0019
Aug ’25n/a
€302.76
0%
17.11%€462.97€231.49€268.0019
Jul ’25n/a
€287.29
0%
20.43%€441.39€216.57€278.0019
Jun ’25n/a
€283.65
0%
20.54%€437.45€214.64€284.0019
May ’25n/a
€284.75
0%
20.62%€435.52€213.69n/a18
Apr ’25n/a
€289.51
0%
19.88%€436.41€216.15n/a18
Mar ’25n/a
€296.27
0%
19.26%€443.97€219.89n/a18
Feb ’25n/a
€319.64
0%
19.54%€482.68€241.34n/a18
Jan ’25n/a
€324.34
0%
19.55%€498.49€237.63n/a19
€356.14
Fair Value
1.6% overvalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/22 17:03
End of Day Share Price 2026/01/22 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Roche Holding AG is covered by 51 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John StaszakArgus Research Company
Gerhard SchwarzBaader Helvea Equity Research
Emily FieldBarclays